Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in ALS
NCT06527222Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranolazine in amyotrophic lateral sclerosis (ALS) (3 arms). Primary endpoints: Frequency of Treatment-Emergent Adverse Events at 28 weeks, Tolerability of treatment assignment at 28 weeks and 9 more. Started Apr 2025; status: recruiting.
02
Drugs
ranolazine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06527222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527222.